All In Biotech

Drug Trial Radar · NCT05597163

Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents

A Multicenter, Double-blind, Randomized, Controlled Clinical Study of the Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents

Last checked: Nov 20, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

588

Planned (sponsor's estimate)

Start

Jan 15, 2023

Primary completion

Nov 1, 2024

Study completion Nov 1, 2025

Sponsor

Lead sponsor
Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Peking University People's Hospital; Shandong University of Traditional Chinese Medicine
First posted
Oct 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy and safety of three low-concentration atropine sulfate eye drops (0.01%, 0.025% and 0.05%) in controlling the progression of myopia in Chinese children and adolescents through a two-year clinical trial.

Conditions

  • Myopia, Progressive

Interventions

  • low concentration atropine (0.01%)Drug

    0.01% atropine eye drop

  • low concentration atropine (0.025%)Drug

    0.025% atropine eye drop

  • low concentration atropine (0.05%)Drug

    0.05% atropine eye drop

  • PlaceboDrug

    Placebo eye drop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of SE changes over -0.75DTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.